Clene Inc. (NASDAQ: CLNN) Is ‘One to Watch’
In June 2023, The Lancet’s eClinicalMedicine journal published combined detailed analyses of Clene’s Phase 2 RESCUE-ALS study and its open-label extension trial In June 2023, Clene announced the closing of a $40 million underwritten public offering with potentially up to an additional $130 million from future warrant exercises As of January 2023, Clene had more than 150 issued patents worldwide and approximately 20 patents pending worldwide on top of many trade secrets Clene owns worldwide rights to commercialize its therapeutics but is looking for a partner to advance the MS indication Clene (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on…
